Given this clinical distribution, our primary aim was to directly address this research gap and investigate the effects of the JNK inhibitor in the context of the more prevalent MYCN-non-amplified disease, relevant to the broad majority of NB patients [5]. The gene discussed is MAPK8; the disease is neuroblastoma.